Introduction of a single isomer beta agonist.
The release of levalbuterol offers the first approved single-isomer beta agonist for oral inhalation. Data from in vitro studies support the concept that S albuterol is not inactive and may have properties antagonistic to bronchodilation. There is some variability in the results of clinical studies with the separate isomers of albuterol, which suggests the need for further study. The introduction of levalbuterol into general clinical use in managing asthma and chronic obstructive disease should begin to offer additional information on the effects of a single isomer beta agonist in comparison to previous racemic mixtures.
Rau
J L
JL
Cardiopulmonary Care Sciences, Georgia State University, Atlanta 30303, USA. jrau@gsu.edu
D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000737:chemistry; D000420:Albuterol / Q000737:chemistry; D001993:Bronchodilator Agents / Q000737:chemistry; D006801:Humans; D007536:Isomerism
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D000420:Albuterol